QPPV.COM KNOWLEDGE ASSESSMENT

Lirafugratinib (Lyrfigtu): FGFR2-Targeted Cholangiocarcinoma Development and Pharmacovigilance

Test your understanding of the concepts covered by Lirafugratinib (Lyrfigtu): FGFR2-Targeted Cholangiocarcinoma Development and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why is dose interruption or reduction important information in a lirafugratinib safety case?

It can document the clinical response to toxicity and help interpret recurrence, exposure and outcome. It replaces the need to document the adverse event itself. It proves that the adverse event was caused by the medicine. It is an administrative detail with no potential relevance to benefit-risk assessment.

Question 2 of 10 A patient develops Grade 2 RPED while receiving lirafugratinib. Which management pathway is described in the article?

Continue the same dose until visual symptoms become severe. Interrupt treatment and, after resolution, resume at a reduced dose in accordance with the label. Add a phosphate binder and continue the current dose. Permanently discontinue treatment in all patients with Grade 2 RPED, without considering resolution.

Question 3 of 10 What does a high frequency of dose interruption and reduction in REFOCUS indicate for routine safety assessment?

Treatment tolerability was often managed dynamically, so adverse-event incidence alone may not describe the treatment burden. The study provides no safety information because most patients changed dose. Dose modification proves that treatment was ineffective. The frequency means permanent discontinuation occurred in most patients.

Question 4 of 10 Which statement most accurately describes the pivotal REFOCUS evidence supporting FDA approval?

A randomized comparison established superior overall survival over standard therapy in all cholangiocarcinoma. A single-arm study showed antitumour activity in a previously treated, FGFR2 fusion/rearrangement-positive population that was naïve to FGFR inhibitor treatment. A study of untreated, unselected cholangiocarcinoma established preventive benefit. A comparative study showed that lirafugratinib was safer than every earlier FGFR inhibitor.

Question 5 of 10 An asymptomatic patient has Grade 1 RPED identified on scheduled OCT. Which approach is most consistent with the label described in the article?

Continue treatment with periodic ophthalmological evaluation. Permanently discontinue treatment immediately in every case. Continue treatment without further eye assessment because there are no symptoms. Reduce the dose automatically without assessing the ophthalmological finding.

Question 6 of 10 What is the most appropriate interpretation of the reported 46% objective response rate in REFOCUS?

It proves that treatment increases survival compared with another available therapy. It indicates tumour responses in the studied population but does not, by itself, establish comparative survival benefit. It estimates the proportion of all patients with cholangiocarcinoma who will respond. It shows that 46% of patients can remain on treatment without dose modification.

Question 7 of 10 A safety analyst compares lirafugratinib reports with reports from an unselected cholangiocarcinoma population. What is the key interpretive concern?

The lirafugratinib population is molecularly selected and may differ in treatment history, so the exposure and clinical context should be preserved. Molecular selection makes adverse-event data unsuitable for any safety analysis. The populations can be considered interchangeable because they share the same cancer diagnosis. Only patients with complete response should be included in safety comparisons.

Question 8 of 10 A patient improves after lirafugratinib is withheld for an adverse event. What is the most appropriate interpretation?

Improvement during interruption supports a possible relationship but does not prove causality. Improvement establishes causality and rules out other explanations. Improvement is irrelevant because the patient has cancer. Improvement means the event should not be recorded as an adverse event.

Question 9 of 10 Why should phosphate laboratory abnormalities be assessed alongside clinical findings such as calcinosis or vascular calcification?

The clinical consequences can distinguish an isolated laboratory change from consequential soft-tissue mineralisation. Laboratory values are irrelevant once a patient reports muscle cramps. A phosphate increase establishes calciphylaxis even without clinical evidence. Soft-tissue findings are expected only when FGFR1 is inhibited and therefore cannot be relevant to lirafugratinib.

Question 10 of 10 Which statement best characterizes the embryo-fetal risk information in the initial U.S. label?

Adequate human pregnancy data establish that fetal risk is absent. Animal findings support an embryo-fetal toxicity warning, while adequate human pregnancy data were not available. Pregnancy exposure is not relevant because the medicine is used only in older adults. The label recommends contraception only for female patients, with no advice for male patients.

QPPV.com

Lirafugratinib (Lyrfigtu): FGFR2-Targeted Cholangiocarcinoma Development and Pharmacovigilance

Cookie Settings